Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing.

Frontiers in genetics·2024
Same author

External validation of a model to predict risk of keratinocyte skin cancer after renal transplantation in a Western European cohort.

The British journal of dermatology·2020
Same author

Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

A new HLA-C*05 allele, HLA-C*05:156, characterized by full-length hemizygous sequencing.

HLA·2018
Same author

Saddlebags: A software interface for submitting full-length HLA allele sequences to the EMBL-ENA nucleotide database.

HLA·2017
Same author

Description of four new HLA alleles in the Finnish population: A*03:283N, A*68:167, C*03:327, C*03:361.

HLA·2017

Related Experiment Video

Updated: Jul 6, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

Luminex donor-specific crossmatches.

E V A Billen1, C E M Voorter, M H L Christiaans

  • 1University Hospital Maastricht, Maastricht, The Netherlands.

Tissue Antigens
|April 3, 2008
PubMed
Summary

A donor-specific Luminex crossmatch (LumXm) shows high accuracy for human leukocyte antigen (HLA) class I antibody detection but has uncertain validity for class II, particularly DQ and DP. This impacts donor organ allocation decisions.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Related Experiment Videos

Last Updated: Jul 6, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Area of Science:

  • * Immunology
  • * Transplantation immunology
  • * Clinical diagnostics

Background:

  • * Luminex bead-based assays are crucial for identifying human leukocyte antigen (HLA) antibodies in recipient sera for donor organ allocation.
  • * A donor-specific Luminex crossmatch (LumXm) is desirable to enhance specificity in pre-transplant evaluations.
  • * Existing flow cytometric crossmatch (FCXm) methods have limitations in specificity and can yield false positives.

Purpose of the Study:

  • * To evaluate the clinical utility and accuracy of a donor-specific Luminex crossmatch (LumXm) for detecting HLA class I and II antibodies.
  • * To compare LumXm performance against established flow cytometric crossmatch (FCXm) and Luminex single antigen (SA) testing.
  • * To determine the reliability of LumXm for specific HLA loci, including DR, DQ, and DP.

Main Methods:

  • * Luminex crossmatch (LumXm) assays were performed using donor HLA-coated beads on 88 pre- and post-transplant sera from 18 recipients.
  • * Results were compared with existing flow cytometric crossmatch (FCXm) data and Luminex single antigen (SA) testing.
  • * Sensitivity and specificity of LumXm were calculated for both HLA class I and class II antibodies.

Main Results:

  • * LumXm demonstrated high sensitivity (89%) and specificity (98%) for detecting HLA class I antibodies, correlating well with T-cell positive FCXm.
  • * For HLA class II antibodies, LumXm showed lower sensitivity (68%) and specificity (97%), with discrepancies noted in 15% of cases.
  • * LumXm exhibited insufficient reactivity for HLA-DQ and HLA-DP antibodies, suggesting potential false negatives and positives for these specificities.

Conclusions:

  • * Luminex crossmatch (LumXm) is a valid and accurate method for detecting donor-specific HLA class I antibodies, aiding organ allocation.
  • * The reliability of LumXm for HLA class II antibody detection, particularly for DQ and DP, remains uncertain and requires further investigation.
  • * While LumXm shows promise, its application for class II crossmatching may need refinement to ensure accurate donor-recipient compatibility assessment.